Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts at least 350 cells/μl in Rural Uganda. HIV antiretroviral therapy (ART) is being rapidly scaled up in sub-Saharan Africa, including recently patients with CD4 T-cell counts above 350 cells/μl. However, concerns persist about adherence and virologic suppression among these asymptomatic, high CD4 cell count individuals. To determine the virologic efficacy and safety of ART among asymptomatic HIV-positive Ugandan adults with high CD4 cell counts at least 350 cells/μl via a streamlined model of care we used prospective nonrandomized clinical study (EARLI Study: clinicaltrials.gov NCT#01479634).
GlobalResearch at UCSF presents the broad scope of health research that is being conducted by UCSF researchers worldwide